COMMUNIQUÉS West-GlobeNewswire

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
21/05/2026
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose [...]
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
21/05/2026
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully [...]
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
21/05/2026
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical [...]
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
21/05/2026
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline
21/05/2026
SAN MATEO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Asher Biotherapeutics (Asher Bio), a clinical-stage biotechnology company developing precisely-targeted immunotherapies for cancer, today announced two upcoming [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/05/2026
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease
21/05/2026
European designation follows U.S. FDA Orphan Drug Designation previously granted for the same indication Landmark KIDCARE trial demonstrated superiority of infliximab over standard retreatment in resistant Kawasaki [...]
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
21/05/2026
Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS ® (zongertinib tablets) as an initial treatment option in HER2 ( ERBB2 )-mutant [...]
GENFIT : Information financière du premier trimestre 2026 et point sur les activités de la Société
21/05/2026
Trésorerie et équivalents de trésorerie s’élevant à 136,1 millions d’euros au 31 mars 2026 Chiffre d’affaires de 9,6 millions d’euros pour les trois premiers mois de 2026, provenant des redevances issues des ventes d’ [...]
NMDP Gala in New York City Raises Record-Breaking $660,000 Enabling More Patients to Receive Life-Saving Cell Therapy
21/05/2026
Sanofi Honored with Corporate Leadership Award; Wanda and Robert Zimmer Serve as Honorary Chairs; Sherry Graves Hope Fund for Patient Financial Support Established MINNEAPOLIS, May 21, 2026 (GLOBE NEWSWIRE) -- NMDP℠ [...]
NANOBIOTIX annonce les modalites definitives de son offre globale sursouscrite a hauteur de 85 millions d’euros
21/05/2026
PARIS et CAMBRIDGE, Mass., 21 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
TME PHARMA ANNONCE LA CONVOCATION DE L'ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES DE 2026
21/05/2026
TME PHARMA ANNONCE LA CONVOCATION DE L'ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES DE 2026 Berlin, Allemagne, le 21 mai 2026, 18 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), Une société de biotechnologie [...]
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
21/05/2026
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS Berlin, Germany , May 21, 2026, 18.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company [...]
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
21/05/2026
WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to [...]
Seven Arrows Recovery Expands Public Education Efforts Around Forward Facing, Nervous System Centered Addiction Treatment
21/05/2026
The Arizona residential treatment center introduces broader awareness of its trauma informed and salutogenic recovery model through Forward Facing Accelerated Recovery™ Elfrida, ARIZONA, May 21, 2026 (GLOBE NEWSWIRE [...]
The Joint Corp. Announces Milind Pant Elected as Director
21/05/2026
- Global Executive with Extensive Digital and International Franchise-Led Growth Experience - SCOTTSDALE, Ariz., May 21, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of [...]
Paul Cobbo to head leading Brisbane NDIS provider Orange Plan Management
21/05/2026
Brisbane, QUEENSLAND, May 21, 2026 (GLOBE NEWSWIRE) -- Paul Cobbo has been appointed General Manager of nationally recognised NDIS plan manager Orange Plan Management. He brings a decade of experience with him gained [...]
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
21/05/2026
Cash and cash equivalents totaled €136.1 million as of March 31, 2026 €9.6 million in revenue for the first three months of 2026, from royalties on Ipsen’s sales of Iqirvo® (elafibranor) Positive momentum across all [...]

Pages